Vivo Capital LLC Buys 595,250 Shares of Silence Therapeutics plc (NASDAQ:SLN)

Vivo Capital LLC lifted its position in Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 116.7% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 1,105,454 shares of the company's stock after purchasing an additional 595,250 shares during the period. Silence Therapeutics comprises approximately 1.9% of Vivo Capital LLC's portfolio, making the stock its 12th biggest holding. Vivo Capital LLC owned about 3.69% of Silence Therapeutics worth $23,878,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. SG Americas Securities LLC bought a new position in Silence Therapeutics during the 4th quarter valued at approximately $110,000. Parkman Healthcare Partners LLC raised its holdings in shares of Silence Therapeutics by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company's stock valued at $4,046,000 after acquiring an additional 40,063 shares in the last quarter. Finally, Lynx1 Capital Management LP purchased a new stake in Silence Therapeutics in the third quarter worth $2,315,000. 98.73% of the stock is owned by hedge funds and other institutional investors.

Silence Therapeutics Stock Down 0.1 %

NASDAQ SLN traded down $0.02 during trading hours on Friday, reaching $21.61. 125,885 shares of the company's stock traded hands, compared to its average volume of 150,450. Silence Therapeutics plc has a 52-week low of $4.84 and a 52-week high of $27.72. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.56 and a quick ratio of 4.56. The firm has a 50-day simple moving average of $23.01 and a 200 day simple moving average of $17.55. The firm has a market cap of $646.64 million, a PE ratio of -14.80 and a beta of 1.41.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last released its quarterly earnings data on Wednesday, March 13th. The company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.22). Silence Therapeutics had a negative net margin of 171.41% and a negative return on equity of 262.17%. The firm had revenue of $2.61 million for the quarter, compared to the consensus estimate of $11.46 million. Sell-side analysts anticipate that Silence Therapeutics plc will post -1.38 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $75.00 price objective on shares of Silence Therapeutics in a research report on Friday, March 15th. Morgan Stanley restated an "overweight" rating and issued a $45.00 price objective on shares of Silence Therapeutics in a report on Monday, April 22nd. Chardan Capital upped their target price on Silence Therapeutics from $26.00 to $42.00 and gave the stock a "buy" rating in a report on Thursday, March 14th. Finally, BMO Capital Markets assumed coverage on Silence Therapeutics in a research report on Wednesday, January 31st. They issued an "outperform" rating and a $67.00 target price for the company.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.